about
The use of neuropathic pain drugs in children with sickle cell disease is associated with older age, female sex, and longer length of hospital stay.Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.Early insights into the neurobiology of pain in sickle cell disease: A systematic review of the literature.Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.Sickle cell disease in mice is associated with sensitization of sensory nerve fibers.Thinking beyond sickling to better understand pain in sickle cell disease.Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study.The development of targeted new agents to improve the outcome for children with leukemia.Patient-reported neuropathic pain in adolescent and young adult cancer patients.Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.Perception of pain among pediatric patients with sickle cell pain crisis.Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.Endothelin-Type A receptors mediate pain in a mouse model of sickle cell disease.Neuropathic pain in patients with sickle cell disease: a cross-sectional study assessing teens and young adults.Sickle cell disease: a natural model of acute and chronic pain.
P2860
Q34734865-5034FB66-7DC6-4AB3-B0D6-FB8EF582096DQ35417108-0E3D8ECC-DF60-4BFC-988A-6A7DF11ABFC4Q35889294-F72667E8-8269-42DE-AAFC-FF9AB8B1CF43Q36349495-B75A8CF4-1A48-4F85-86DA-71BA2F72E964Q37070937-EFFD1503-1378-46C7-A9A9-02C298CCBA9DQ38204781-8ABA0B58-0C4D-41B9-8E17-013A7902FC30Q38892119-786F8552-8302-4EFB-B371-9E0019D55311Q38964974-FE121925-4E76-47A0-8310-2841F9FFC4E4Q39146230-BC1EC2BB-6ABB-4C53-852B-DB42FD2C251FQ41635275-D3B2C2D6-7A1B-44FB-98DF-E473A3C12FECQ43426236-926E199C-5F41-45B4-A39C-FF4E994CBABAQ47253135-3B373EF6-D094-4ABA-8394-BE4AA710789BQ52316849-519E0227-3969-4A99-B264-2C1C32EE79CCQ52653304-532872F0-F870-4B11-99E8-4AC6B64E16CCQ52810606-460BCDBE-A547-4E76-A7EB-F8E1612B6FCDQ55053106-6099B456-8C9D-4D80-9D77-FF43523E1A04
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Neuropathic pain in patients with sickle cell disease.
@ast
Neuropathic pain in patients with sickle cell disease.
@en
type
label
Neuropathic pain in patients with sickle cell disease.
@ast
Neuropathic pain in patients with sickle cell disease.
@en
prefLabel
Neuropathic pain in patients with sickle cell disease.
@ast
Neuropathic pain in patients with sickle cell disease.
@en
P2093
P2860
P356
P1476
Neuropathic pain in patients with sickle cell disease.
@en
P2093
Amanda M Brandow
Julie A Panepinto
Rebecca A Farley
P2860
P304
P356
10.1002/PBC.24838
P577
2013-10-26T00:00:00Z